Table 3.

Molecular subtypes of breast cancer and their prognosis. Abbreviations: ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor 2; Ki-67 = marker of proliferation Kiel 67.

MOLECULAR SUBTYPE	PROGNOSTIC
Luminal A (ER+ and/or PR+, HER−)	-Best prognosis of all subtypes -Low Ki67 expression -Good response to hormonal treatment
Luminal B (ER+ and/or PR+, HER+)	-Less favorable prognosis compared to Luminal A -High Ki67 expression -Good response to chemotherapy
HER2 enriched (ER−, PR−, HER2+)	-Poor perspective -Likely high-grade -Aggressive course -Anti-HER2 therapy improves prognosis
Triple Negative (ER−, PR−, HER2−)	-Worst prognosis -More aggressive -High recurrency -More common in younger women -Complex management necessary